SK Biopharm (326030) financial statements
+64223.0%since 2018
- FY2025 revenue
- ₩706.7B▲ +29.1%
- FY2025 net income
- ₩267.0B▲ +10.9%
- FY2025 diluted EPS
- ₩3,409.00▲ +10.9%
- FY2025 free cash flow
- ₩169.4B▲ +81.2%
SK Biopharm income statement
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 706,741 | 547,596 | 354,892 |
| Gross profit | 663,840 | 504,495 | 320,809 |
| Operating income | 203,938 | 96,340 | -37,522 |
| Pretax income | 150,884 | 72,596 | -43,858 |
| Net income | 266,950 | 240,738 | -32,883 |
| Diluted earnings per share | 3,409.00 | 3,074.00 | -420.00 |
SK Biopharm balance sheet
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 307,771 | 322,807 | 239,700 |
| Total assets | 1,198,309 | 1,036,811 | 723,171 |
| Total liabilities | 372,039 | 462,827 | 402,219 |
| Total equity | 826,270 | 573,984 | 320,951 |
| Long-term debt | 0 | 0 | 94,484 |
SK Biopharm cash flow statement
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 176,334 | 94,900 | -94,201 |
| Capital expenditure | -6,892 | -1,395 | -2,385 |
| Free cash flow (derived) | 169,442 | 93,505 | -96,586 |
Quarterly highlights
| KRW millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 |
| Revenue (derived) | 258,418 | 247,367 | 227,886 | 194,360 |
| Operating income (derived) | 116,283 | 97,064 | 89,768 | 46,278 |
| Net income (derived) | 54,341 | 85,065 | 105,162 | 136,593 |
| Diluted earnings per share | 694.00 | 1,086.00 | 1,343.00 | n/a |
| Operating cash flow (derived) | 95,016 | 78,148 | 17,918 | 87,004 |
| Total assets | 1,395,166 | 1,418,765 | 1,320,421 | 1,198,309 |
SK Biopharm major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| SK | 50.1% | 39,268,671 | 30 March 2026 |
| 국민연금공단 | 6.0% | 4,697,035 | 31 March 2026 |
SK Biopharm DART filings
| Filed | Form | Type |
|---|---|---|
| 15 November 2026 | Quarterly Report | Quarterly report |
| 25 August 2026 | Major Matters Report | Current report |
| 13 August 2026 | Semiannual Report | Half-year report |
| 14 May 2026 | Quarterly Report | Quarterly report |
| 17 March 2026 | Business Report | Annual report |
| 13 November 2025 | Quarterly Report | Quarterly report |
| 13 August 2025 | Semiannual Report | Half-year report |
| 14 May 2025 | Quarterly Report | Quarterly report |
Common questions
What was SK Biopharm's revenue in fiscal 2025?
SK Biopharm reported ₩706.7 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 29.1% from fiscal 2024.
What was SK Biopharm's net income in fiscal 2025?
SK Biopharm reported net income of ₩267.0 billion for fiscal 2025, the year ended 31 December 2025, up 10.9% from fiscal 2024. Diluted earnings per share were ₩3,409.00.
What was SK Biopharm's free cash flow in fiscal 2025?
SK Biopharm had ₩169.4 billion in free cash flow in fiscal 2025. Operating cash flow was ₩176.3 billion and capital expenditure was ₩6.9 billion.
What were SK Biopharm's total assets at the end of fiscal 2025?
SK Biopharm reported total assets of ₩1.2 trillion at the end of fiscal 2025, the year ended 31 December 2025.
How much SK Biopharm history do I get?
Every account gets the full history, annual and quarterly, with first reported values and as of dates.
Start with a free key
Free $10 credits every month, no card.Free $10 credits a month, no card.